Bank of India Mid Cap Fund

Bank of India Mid Cap Fund has delivered a 1Y SIP XIRR of 11.94%, significantly below the category average of 21.6% for the same period. On a lump-sum basis, the fund has also trailed the NIFTY Midcap 150 benchmark across all measured windows, with a 1Y Fund CAGR of 8.07% versus the benchmark's 10.63%. Negative alpha across all time horizons, ranging from -1.93% at 1Y to -1.05% at 15Y, indicates persistent underperformance after adjusting for market risk.

The fund exhibits a beta of 0.85, meaning it moves less than the benchmark in both directions, with nearly identical upside capture (83.72%) and downside capture (83.96%). This symmetric sub-market exposure has not improved risk-adjusted returns, as the negative alpha demonstrates. The maximum drawdown of just -0.12% with a 37-day recovery suggests the measured drawdown data reflects a limited or unusually calm observation window rather than the fund's true long-term risk profile.

The top 10 holdings account for roughly 36.6% of the portfolio across 50 total stocks, indicating reasonable diversification at the stock level. Pharmaceuticals is the largest sector at 13.9%, led by Abbott India (5.28%) and Aurobindo Pharma (5.11%), followed by Capital Markets (7.5%) and Auto Components (6.8%). The portfolio spans defensive sectors like pharma and financials alongside cyclical exposures such as cement, oil, and metals, providing a balanced sector spread.

The fund sits well below category peers, with its 1Y SIP XIRR of 11.94% trailing the category average of 21.6% by nearly 10 percentage points. Its consistent negative alpha across 1Y to 15Y windows points to a structural lag versus the benchmark rather than a short-term anomaly. Investors seeking mid-cap exposure have likely been better served by category peers on both SIP and lump-sum bases.

This fund is suitable only for investors with high risk tolerance and a long time horizon of at least 5 to 7 years, given mid-cap volatility and the fund's current underperformance. Existing investors should weigh the persistent negative alpha against the fund's diversified portfolio and below-market beta before adding fresh capital. Most new investors would be better served by mid-cap funds with stronger category-relative performance, and this fund should be treated as a watchlist candidate rather than a first choice.

• Diversified portfolio of 50 stocks with the top 10 holdings limited to roughly 36.6% of NAV, avoiding excessive single-stock concentration
• Balanced sector allocation spanning defensive pharma (13.9%) and financials alongside cyclical cement, oil, and metals exposure
• Below-market beta of 0.85 with nearly equal upside and downside capture, offering somewhat muted volatility relative to the NIFTY Midcap 150

• 1Y SIP XIRR of 11.94% trails the category average of 21.6% by a wide margin, indicating weak peer-relative performance
• Consistently negative alpha across all time horizons from 1Y (-1.93%) to 15Y (-1.05%) shows persistent underperformance versus the benchmark
• Lump-sum CAGR of just 2.62% over 3Y versus the benchmark's 3.43% reflects weak absolute returns even before adjusting for the 1.5% expense ratio